Clinical significance of CD200 expression in newly diagnosed multiple myeloma patients and dynamic changing during treatment

Abstract

The aim of our study was to determine the impact of CD200 expression in newly diagnosed myltiple myeloma (MM) patients. CD200⁺ patients had significantly shorter median overall survival time (OS) than CD200^– patients (41.0 months vs. not reached, p = .009). The ratio of CD4⁺ to CD8⁺ T cells was lower in CD200⁺ patients and this reduction was significantly related to the increase of CD8⁺ T cells (p = .021). Moreover, we analyzed dynamic changes of CD200 expression in 47 CD200⁺ patients during treatment. Thirty-eight (80.9%) patients switched to CD200^– during treatment. Those patients had a favorable survival compared with the others (median OS, 65.0 vs. 32.0 months, p < .001; median PFS, 29.0 vs. 11.5 months, p = .027). We concluded that CD200 expression is an independent marker for MM prognostic estimation during treatment.

Keywords:

• CD200
• prognosis
• multiple myeloma
• flow cytometry

Authors’ contributions

Lijuan Chen and Jianyong Li designed the work. Qinglin Shi, Chao Wu, Yuanyuan Jin, Xiaoyan Qu, Wenmin Han and Run Zhang analyzed and interpreted the patient data. Sishu Zhao and Yujie Wu performed the experiments. Qinglin Shi and Run Zhang wrote the paper. All authors read and approved the final manuscript.

Ethical approval

Our study follows the principles of the Declaration of Helsinki.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

All data generated or analyzed during this study are included in this published article.

Additional information

Funding

This work was supported by National Natural Science Foundation of China [81670199]; Jiangsu Province’s Medical Elite Program [ZDRCA2016015].